FDA Amplifies Cross-Center Collaboration with the Creation of the Rare Disease Innovation Hub

November 7, 2024

Reading Time : 4 min

Roughly one out of every ten people in the United States are affected by rare diseases. Many of these conditions are life‑threatening, and most lack FDA-approved treatments. Developing therapies for rare diseases, however, is challenging for various reasons, including the complex biology involved, the limited understanding of disease progression (i.e., the natural history), and the difficulties of conducting clinical trials in small patient populations. FDA engages with many stakeholders in the rare disease community to inform the development of safe and effective therapies and has made, in recent months, major strides in amplifying these efforts.

This past summer, FDA created the Rare Disease Innovation Hub (the Hub), which seeks to strengthen and unify efforts between FDA’s Center for Drug Research and Evaluation (CDER) and Center for Biologics Evaluation and Research (CBER).1The Hub will be a central point of connection for the centers and the larger rare disease community and will leverage cross‑agency expertise to accelerate the development of new treatments. Although a range of rare diseases will be addressed, the Hub will have a particular focus on diseases with small patient populations and complex natural histories not yet fully understood.

The Hub is co‑led by the directors of CDER and CBER—Drs. Patrizia Cavazzoni and Peter Marks—and has three primary functions:

  1. Serve as the single point of connection for the rare disease community—including patients, caregivers, trade organizations and scientific and academic organizations—and help the larger rare disease community navigate key intersections across FDA.
  2. Enhance intercenter collaboration to address common scientific, clinical and policy issues in rare disease product development and ensure consistency across offices and Centers.
  3. Advance regulatory science with initiatives focused on novel endpoints, biomarker development and assays, innovative trial design, real world evidence and statistical methods.

Alongside their roles as directors of the Hub, Drs. Cavazzoni and Marks also co‑chair the Rare Disease Innovation Steering Committee and will work closely with leadership in FDA’s Center for Devices and Radiological Health, Oncology Center of Excellence, Office of Orphan Products Development and Office of Combination Products. As directors, Drs. Cavazzoni and Marks hope to “disseminate [their] shared vision and develop a comprehensive cross‑center strategic agenda to align efforts, identify and enable innovative approaches, and streamline communication to better serve the rare disease community.”

Additionally, the new senior leadership position created for the Hub, the Director of Strategic Coalitions (Associate Director of Rare Disease Strategy), will play a pivotal role. The associate director will report to both directors and will act as the primary contact for external stakeholders, identify their needs and promote FDA staff engagement so that insights from these interactions inform FDA approaches and policies. Another key responsibility of the associate director is to build strategic coalitions between CDER and CBER to harness the deep expertise within each Center and tackle shared challenges in rare disease treatment.

Although CDER and CBER already collaborate, the creation of more formal structures for their interactions will strengthen engagement. These structures include regular meetings and dedicated workstreams on cross-cutting rare disease‑related issues, such as the use of real‑world data, clinical trial methodology, and statistical approaches. This intentional collaboration will leverage insights from existing rare disease programs and pilot programs—such as the CDER Accelerating Rare disease Cures (ARC) Program, the CBER Rare Disease Program, the Rare Disease Endpoint Advancement (RDEA) Pilot Program, and the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. Unifying the Centers’s efforts is poised to bring greater advances in identifying promising drug targets and developing gene therapies for rare disease patients.

In recent weeks, FDA has made major steps towards establishing the Hub. On October 16, 2024, FDA hosted a public meeting to gather feedback from the rare disease community. The meeting was attended by the Hub’s leadership, patient advocates, academic researchers, members of the regulated industry, and many others to discuss the Hub’s priorities and how the Hub can best engage with the community. Last week, FDA announced that it had selected Amy Comstock Rick, J.D., to serve as the Director of Strategic Coalitions for the Hub. Ms. Rick previously served as a principal consultant at Leavitt Partners and the President and CEO of the Food & Drug Law Institute. She brings over twenty years of experience as a leader in health care, biomedical research and nonprofit communities.

The Hub reflects FDA’s ongoing commitment to the development of safe and effective therapies for rare diseases. In light of these efforts, interested parties can anticipate that the issue of standards for approving rare disease therapies, especially ultra rare diseases, is likely to be an area of focus in the next user fee cycle. It is likely that rare diseases will also be an area of focus in the next round of user fee negotiations.

For more information, please visit the FDA Rare Disease Innovation Hub website.


1 In 2023, more than half of all novel drugs and biologics approved by CDER and CBER were intended for the prevention, diagnosis or treatment of a rare disease or condition.

Share This Insight

Previous Entries

Eye on FDA

September 29, 2025

FDA recently released two draft guidance documents for industry related to cell and gene therapy (CGT) products as the agency seeks to advance the efficient development and review of safe and effective CGT products and fulfill related commitments set forth in the 2022 reauthorization of the Prescription Drug User Fee Act (PDUFA VII). This latest guidance may be of particular interest to CGT developers and various patient groups.

...

Read More

Eye on FDA

September 24, 2025

On Tuesday, September 23, 2025, FDA published guidance titled “Consideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency.” The guidance, a draft of which was published on May 6, 2024, specifies the factors that FDA intends to assess in deciding whether to issue an enforcement discretion policy with regard to in vitro diagnostics (IVD) manufacturers offering unapproved IVDs, among other devices, during a declared emergency. These factors include:

...

Read More

Eye on FDA

September 23, 2025

Last week, the U.S. Food and Drug Administration (FDA) issued a proposed rule to revoke the color additive listing for Orange B, a synthetic dye historically used on the casings and surfaces of frankfurters and sausages. This action is part of the broader “Make America Healthy Again” (MAHA) initiative to phase out petroleum-based foods from the American food supply by the end of 2026 and efforts to modernize the agency’s regulations.

...

Read More

Eye on FDA

September 12, 2025

The White House’s Make America Healthy Again (MAHA) Commission, led by the Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., released its highly anticipated strategy outlining a multi-agency approach focused on addressing childhood chronic disease. The strategy builds on the Commission’s inaugural health assessment, a report which examined the rising rates of childhood chronic diseases in the country and identified four primary drivers: poor diet due to consumption of ultra-processed foods (UPFs), exposure to environmental chemicals; increased technological use; and overmedicalization. To combat these challenges, the strategy released on September 9, 2025, outlines a four-prong approach which provides further insight into the areas the administration sees as key areas of MAHA going forward: advancing research, realigning incentives, increasing public awareness and fostering private sector collaborations.

...

Read More

Eye on FDA

September 8, 2025

On September 3, 2025, the Food and Drug Administration (FDA) announced Rare Disease Evidence Principles (RDEP) with processes aimed at providing greater predictability and facilitating the development and review of drugs intended to treat rare diseases with very small patient populations and significant unmet medical needs driven by a known genetic defect. In conjunction with the agency’s announcement of the new processes jointly proposed by the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the agency also unveiled additional information regarding eligibility and the potential for post-marketing requirements for those sponsors who participate in it.

...

Read More

Eye on FDA

August 27, 2025

Food dye reform has been an area of focus for the Trump administration as part of its Make America Healthy Again (MAHA) initiative, giving momentum to an effort the Food and Drug Administration (FDA) had already started by banning Red No. 3 for use in food and ingested drugs. FDA has continued to prioritize this work by taking actions to phase out the use of synthetic dyes and move to natural dyes since calling for these changes earlier this year, as discussed in our previous blog on the related announcement by the administration.

...

Read More

Eye on FDA

August 12, 2025

Last week, former Food and Drug Administration (FDA) Commissioner David Kessler submitted a citizen petition urging FDA to revoke the generally recognized as safe (GRAS) status of refined carbohydrates used in industrial food processing. The petition follows FDA’s and the United States Department of Agriculture’s (USDA) joint request for information (RFI) to establish a formal definition for ultra-processed foods (UPFs) and offers FDA a legal pathway to change the regulatory status of these ingredients.

...

Read More

Eye on FDA

August 6, 2025

On August 6, 2025, the U.S. Food and Drug Administration (FDA) became the latest governmental agency to confirm that fluoropolymers are both safe and necessary. After an independent safety review of fluoropolymers in medical devices showed no conclusive evidence of health issues, FDA concluded that fluoropolymers are “very unlikely to cause toxicity” because of molecular size and further that they are essential for medical devices to function. As a result, “FDA’s evaluation is that currently there is no reason to restrict their continued use in devices.” This announcement will be a source of relief to the device and diagnostics industries.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.